Real-world delivery rate to third-line chemotherapy in patients with advanced gastric cancer

被引：0
|
作者：
Ueno, Masayuki [1 ]
Doi, Akira [1 ]
Mouri, Hirokazu [1 ]
Yamamoto, Hiroshi [1 ]
Mizuno, Motowo [1 ]
机构：
[1] Kurashiki Cent Hosp, Dept Gastroenterol & Hepatol, Kurashiki, Okayama, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2 - 062
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Chemotherapy re-use versus anti-angiogenic monotherapy as the third-line treatment of patients with metastatic colorectal cancer: a real-world cohort study
    Duan, Jingjing
    Zhu, Lila
    Shi, Yinghui
    Wang, Weixue
    Wang, Tongtong
    Ning, Tao
    Zhang, Le
    Bai, Ming
    Li, Hongli
    Liu, Rui
    Ge, Shaohua
    Wang, Xia
    Yang, Yuchong
    Ji, Zhi
    Wang, Feixue
    Sun, Yansha
    Ba, Yi
    Deng, Ting
    BMC CANCER, 2024, 24 (01)
  • [42] Efficacy and prognosis analyses of apatinib combined with S-1 in third-line chemotherapy for advanced gastric cancer
    Wu, Qiuju
    Fu, Yingchun
    Wen, Wenlong
    Xi, Ting
    Zhao, Guangling
    JOURNAL OF BUON, 2020, 25 (02): : 987 - 994
  • [43] Treatment patterns and characteristics in the second and third-line therapy setting for real-world small cell lung cancer patients.
    Prince, Patricia
    Estrin, Adina
    Supina, Dylan
    Ben-Joseph, Rami
    Boccuti, Anne
    Asubonteng, Kobby
    Rengarajan, Badri
    Fridman, Moshe
    Hanvesakul, Raj
    Taylor, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer
    Takeshi Kawakami
    Nozomu Machida
    Hirofumi Yasui
    Masahiro Kawahira
    Sadayuki Kawai
    Yosuke Kito
    Yukio Yoshida
    Satoshi Hamauchi
    Takahiro Tsushima
    Akiko Todaka
    Tomoya Yokota
    Kentaro Yamazaki
    Akira Fukutomi
    Yusuke Onozawa
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 809 - 814
  • [45] A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer
    Shao, Yingbo
    Luo, Zhifen
    Yu, Yang
    He, Yaning
    Liu, Chaojun
    Chen, Qi
    Zhu, Fangyuan
    Nie, Bing
    Liu, Hui
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [46] Third-line systemic treatment in advanced/metastatic gastric cancer: a comprehensive review
    Chan, Wing-lok
    Lam, Ka-on
    So, Tsz-him
    Lee, Victor Ho-fun
    Kwong, Lai-wan Dora
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [47] Third-Line Chemotherapy with irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients
    Pasquini, Giulia
    Vasile, Enrico
    Caparello, Chiara
    Vivaldi, Caterina
    Musettini, Gianna
    Lencioni, Monica
    Petrini, Lacopo
    Fornaro, Lorenzo
    Falcone, Alfredo
    ONCOLOGY, 2016, 91 (06) : 311 - 316
  • [48] Clinical impact of oral intake in third-line treatment for advanced gastric cancer
    Ogata, T.
    Narita, Y.
    Kumanishi, R.
    Nakazawa, T.
    Matsubara, Y.
    Kato, K.
    Nozawa, K.
    Honda, K.
    Masuishi, T.
    Bando, H.
    Kadowaki, S.
    Ando, M.
    Tajika, M.
    Muro, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S141 - S141
  • [49] Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer
    Kawakami, Takeshi
    Machida, Nozomu
    Yasui, Hirofumi
    Kawahira, Masahiro
    Kawai, Sadayuki
    Kito, Yosuke
    Yoshida, Yukio
    Hamauchi, Satoshi
    Tsushima, Takahiro
    Todaka, Akiko
    Yokota, Tomoya
    Yamazaki, Kentaro
    Fukutomi, Akira
    Onozawa, Yusuke
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (04) : 809 - 814
  • [50] CPT-11+CDDP in patients with metastatic and recurrent gastric cancer as a third-line chemotherapy.
    Yoshida, T
    Murakami, H
    Tsuburaya, A
    Kobayashi, O
    Sairenji, M
    Motohashi, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 364S - 364S
12345